$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Palbociclib belongs to several generations of targeted drugs
2026-02-01 22:25:32
Check Details
The Difference Between Palbociclib and Dalsilide
2026-02-01 22:25:32
Check Details
Palbociclib monthly price
2026-02-01 22:25:32
Check Details
Bemcentinib plus SOC including dabrafenib is well tolerated but does not improve efficacy in metastatic melanoma
2026-02-01 22:25:32
Check Details
Dabrafenib combined with tramatinib in the treatment of BRAF V600 mutated pediatric gliomas
2026-02-01 22:25:32
Check Details
ROAR Study Updates Dabrafenib/Trametinib Cure Benefits in BRAF V600E+ATC
2026-02-01 22:25:32
Check Details
Dabrafenib, tramatinib and Navitoclax combination shows promise for metastatic melanoma
2026-02-01 22:25:32
Check Details
What kind of medicine is Sofosbuvir and Velpatasvir?
2026-02-01 22:25:32
Check Details
What are the side effects of sofosbuvir and velpatasvir?
2026-02-01 22:25:32
Check Details
Sofosbuvir and velpatasvir usage and dosage
2026-02-01 22:25:32
Check Details
Can sofosbuvir and velpatasvir cure hepatitis C? What is the success rate?
2026-02-01 22:25:32
Check Details
When did sofosbuvir and velpatasvir come on the market?
2026-02-01 22:25:32
Check Details
1
2
...
391
392
393
394
395
396
397
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
2
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
3
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
4
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option
5
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
6
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
7
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
8
Vadadustat: Clinical Evidence and Patient Benefits of an Oral HIF-PHI for CKD-Related Anemia
9
Ponatinib vs. Olverembatinib: A Multidimensional Comparison of Third-Generation BCR-ABL Inhibitors
10
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
11
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
12
Chemical Structure of Capivasertib: A Novel AKT Inhibitor